InSysBio to participate in SITC 2024

events
Conference
October 4, 2024

InSysBio announces its participation in SITC’s 39th Annual Meeting which is to be held from November 6-10, 2024, at George R. Brown Convention Center in Houston, TX, USA. InSysBio team is going to present its Mechanistic modeling services and tools to support development of immunotherapies at Booth #1032 and 3 posters in frames of the Meeting, namely:

Saturday, November 9:

  • 536 "Evaluation of various strategies to unleash DNAM1 signaling and block TIGIT/PVRIG axis" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
  • 1064 "Mechanistic translational modeling to predict first-in-human dose for T-cell engager: HPN536 case study" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov
  • 1208 "Comparison of receptor occupancy and optimal doses of PD1xCD40 and PDL1xCD40 bispecific antibodies using physiologically based pharmacokinetic modeling" by Alexandra Diakonova, Dmitry Schelokov, Oleg Demin Jr, Oleg Demin

Check out Booth #1032 and posters at SITC 2024 Annual Meeting!

About InSysBio

InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.

August 2020
MoTuWeThFrSaSu
     
1
2
3
1. 03 Aug 2020 16:00 InSysBio to share new data in frames of its Open Source QSP model of COVID-19 InSysBio has received a new set of results in framework of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
4
5
6
1. 06 Aug 2020 17:51 InSysBio to update its Cytocon DB and to present version 1.2.6.6 InSysBio is glad to present Cytocon DB 1.2.6.6! Cytocon DB team has reviewed 39 articles to introduce new data. It should be outlined that the total number of concentrations within the Database has already exceeded 10 thousand!
7
8
9
10
11
12
13
14
15
16
17
18
19
20
1. 20 Aug 2020 17:18 InSysBio to present the new version of Immune Response Template IRT 3.2.0 acquires new models and extended annotations (Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
21
22
23
24
25
26
27
28
29
30
31
      
Upcoming Events
10.11
InSysBio to take part in ACoP 2024
06.11
InSysBio to participate in SITC 2024
Tags
Latest News
10.09
InSysBio team to publish the new article in PSPJournal
04.09
InSysBio to launch Immune Response Template version 3.6.3 for QSP modeling
22.02
14th InSysBio’s Annual Internal Scientific Meeting
24.01
InSysBio to present the new Plugin for Sublime Text and Heta compiler Online
07.12
InSysBio to release public beta of fIVE Calculator